1-3 of 3
Abdullah A. Masud
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Shaji Kumar, Simon J Harrison, Michele Cavo, Javier de la Rubia, Rakesh Popat, Cristina J. Gasparetto, Vania Hungria, Hans Salwender, Kenshi Suzuki, Inho Kim, Maika Onishi, Grace Ku, Rajvineeth Kumar Pothacamury, Vasudha Sehgal, Abdullah A. Masud, Jeremy A. Ross, Edyta Dobkowska, Philippe Moreau
Journal: Blood
Blood (2021) 138 (Supplement 1): 84.
https://doi.org/10.1182/blood-2021-145757
Published: 2021
Journal Articles

Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

Luciano J. Costa, MD PhD, Nicholas Burwick, MD, Andrzej Jakubowiak, MD PhD, Jonathan L. Kaufman, MD, Fernando Cabanillas, MD, Monique Dail, PhD, Sudeep Karve, Abdullah A. Masud, PhD, Xiaoqing Yang, PhD, Orlando F. Bueno, Sarah Mudd, PhD, Jeremy A. Ross, Faith E. Davies
Journal: Blood
Blood (2020) 136 (Supplement 1): 4–5.
https://doi.org/10.1182/blood-2020-134737
Published: 2020
Journal Articles

A Phase 3, Double-Blind, Placebo-Controlled, Randomized Study Evaluating Navitoclax in Combination with Ruxolitinib in Patients with Myelofibrosis (TRANSFORM-1)

Jalaja Potluri, MD, Jason Harb, PhD, Abdullah A. Masud, PhD, Jessica E. Hutti, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139758
Published: 2020